Ask AI
ProCE Banner Series

Aligning Discovery With Clinical Practice: Applying Expert Consensus Guidelines to Improve Patient Outcomes in CLL/SLL

In collaboration with NCCN, join us for this dynamic, case-based, CME/CE/CPE-certified live symposium, in which an expert panel will discuss current recommendations and emerging strategies for treating patients with CLL/SLL. Sign up now!

Friday Satellite Symposium preceding the ​67th ASH Annual Meeting and Exposition.

  AAPA
  | ACPE
  | AMA
  | ANCC
Who Should Attend

This educational activity is intended for hematologists, medical oncologists, physician associates, nurses, pharmacists, and other healthcare professionals who care for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

All Events

Aligning Discovery With Clinical Practice: Applying Expert Consensus Guidelines to Improve Patient Outcomes in CLL/SLL

Upcoming Events

December

05

2025

7:00 AM - 9:00 AM Eastern Time (ET)

Virtual

Topics

Hematologic malignancies, leukemias, lymphomas

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
This activity's goal is to improve the knowledge, competence, and confidence of learners to integrate new and emerging therapies into practice to improve clinical outcomes in patients with chronic lymphocytic leukemia / small lymphocytic lymphoma.

Target Audience
This educational activity is intended for hematologists, medical oncologists, physician associates, nurses, pharmacists, and other healthcare professionals who care for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Select individualized frontline therapy for patients with CLL/SLL, based on current evidence, recommendations outlined in NCCN Guidelines, expert guidance, and patient medical history and preferences
  • Plan optimal treatment strategies for patients with R/R CLL that integrate recommendations outlined in the NCCN Guidelines, emerging targeted therapy approaches, sequencing therapy based on response to and tolerance of prior therapy, and mechanisms of resistance
  • Devise comprehensive patient education and supportive care strategies for targeted therapy–associated AEs to improve clinical outcomes

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

NCCN designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
NCCN designates this educational activity for a maximum of 2.0 contact hours. This activity offers 1.5 pharmacotherapeutic contact hours for nurses.

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 2.0 contact hours (0.20 CEUs) of continuing education credit. UAN: JA4008196-0000-25-114-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

LogoDescription automatically generated

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification 

A blue and black sign with white textDescription automatically generated

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregated participant data will be shared with the commercial supporters of this activity.

For ABIM MOC points, your information will be shared with the ABIM through NCCN's Joint Accreditation Program and Activity Reporting System (JA-PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving NCCN permission to use this information/data to report your participation to ABIM via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships. In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. Full disclosure of faculty relationships will be made prior to the activity. 

Acknowledgement

Provided by

Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC.

NCCN 2020
CCO 2022

Supporters

Supported by educational grants from AstraZeneca and Lilly.

AstraZeneca

Lilly

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191